Exposure to TNF antagonist therapies induces variations of the gut microbiota in an in vivo model using healthy mice - 07/03/20
Doi : 10.1016/j.jbspin.2019.08.001
Odile Gabay a, ⁎ 
, Jonathan Vicenty a, Autumn Zack-Taylor a, Linda Tiffany a, Grant Wunderlin a, Dylan Smith a, Lismari Reyes-Munoz a, Vivienne Edwards a, Wells W. Wu b, Je-Nie Phue b, Luis Santana-Quintero d, Phuc VinhNguyen Lam c, Kathleen A. Clouse a
, Jonathan Vicenty a, Autumn Zack-Taylor a, Linda Tiffany a, Grant Wunderlin a, Dylan Smith a, Lismari Reyes-Munoz a, Vivienne Edwards a, Wells W. Wu b, Je-Nie Phue b, Luis Santana-Quintero d, Phuc VinhNguyen Lam c, Kathleen A. Clouse a a U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA
b U.S. Food and Drug Administration, Center for Biologicals Evaluation and Research, Facility for Biotechnology Resources, Silver Spring, MD, USA
c U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, HIVE, Silver Spring, MD, USA
d U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Hematology and Oncology Products, Silver Spring, MD, USA
⁎Corresponding author at: FDA/CDER White Oak, Division of Biotechnology Review and Research, Bldg 52/72, Rm2321, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.FDA/CDER White Oak, Division of Biotechnology Review and Research, Bldg 52/72, Rm232110903 New Hampshire AvenueSilver SpringMD20993USA
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | There is currently no study on the impact of biologic therapeutics on the microbiome, despite variable patients’ response to biologics used to treat gut-joint-axis diseases. |
• | We studied microbiome variations resulting from different TNF-antagonist treatments in an in vivo mouse model. |
• | We showed a dysbiosis of the microbiome after treatment in young mice, and identified major bacteria involved in TNF-antagonists exposure. These bacteria were different between males and females. |
Keywords : Gut microbiome, TNF inhibitors, Dysbiosis
Plan
| ☆ | Disclaimer: This manuscript reflects the views of the authors and should not be construed to represent FDA's views or policies. |
© 2019
Publié par Elsevier Masson SAS.
Vol 87 - N° 2
P. 175-178 - mars 2020 Retour au numéro
Article précédent
- Rebound-associated vertebral fractures after stopping denosumab: Report of four cases
- Jolan Dupont, Michaël R. Laurent, Lenore Dedeyne, Frank P. Luyten, Evelien Gielen, Marian Dejaeger
- Effectiveness and tolerance of off-label use of tocilizumab in autoimmune diseases: A Multicenter Study
- Martin Michaud, Olivier Lidove, Boris Bienvenu, Laurent Chiche, Geoffrey Urbanski, TOCIMAI Investigators Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?